Yuxin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuxin Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Shiqiang Li
Florida State University, Tallahassee, FL, USA
3 shared publications An-Ran Wang
2 shared publicationsChongqing Western District Hospital
2 shared publications- Dao Wen Wang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
2 shared publications Jin-Xian Zhu
Chongqing Western District Hospital
2 shared publications- Kun Cheng
Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7734
Mitochondrial Distress Signals at the Heart–Liver Interface: Molecular Links Between MASLD and Heart Failure
Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF) frequently coexist within a shared cardiometabolic environment, yet their mitochondrial abnormalities are stage- and phenotype-dependent rather than uniform. In MASLD, mitochondrial adaptation evolves from increased oxidative metabolism in early steatosis toward impaired respiratory flexibility, oxidative stress, and defective quality control with disease progression, whereas the failing myocardium develops reduced energetic reserve and altered substrate utilization. These organ-specific disturbances can modify mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, stress-responsive endocrine mediators, and extracellular vesicle-associated mitochondrial cargo. However, similar mitochondrial abnormalities or circulating signals in the liver and heart do not by themselves establish direct inter-organ communication. This review distinguishes shared systemic drivers and organ-intrinsic mitochondrial stress from source-resolved cardio-hepatic signaling, highlighting hepatic ketogenesis, fibroblast growth factor 21 (FGF21), mitochondrial DNA (mtDNA)-dependent inflammatory pathways, and extracellular vesicle-mediated cargo transfer as mechanistically distinct examples with different levels of evidence. We further discuss biomarker limitations, HF-related hemodynamic liver injury, and therapeutic strategies ranging from established cardiometabolic unloading to emerging mitochondria-centered interventions. A stage-, phenotype-, and source-resolved framework may improve interpretation of mitochondrial signals and guide future mechanistic and translational studies in the MASLD–HF overlap.
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7734
Open AccessMitochondrial Distress Signals at the Heart–Liver Interface: Molecular Links Between MASLD and Heart Failure
Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF) frequently coexist within a shared cardiometabolic environment, yet their mitochondrial abnormalities are stage- and phenotype-dependent rather than uniform. In MASLD, mitochondrial adaptation evolves from increased oxidative metabolism in early steatosis toward impaired respiratory flexibility, oxidative stress, and defective quality control with disease progression, whereas the failing myocardium develops reduced energetic reserve and altered substrate utilization. These organ-specific disturbances can modify mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, stress-responsive endocrine mediators, and extracellular vesicle-associated mitochondrial cargo. However, similar mitochondrial abnormalities or circulating signals in the liver and heart do not by themselves establish direct inter-organ communication. This review distinguishes shared systemic drivers and organ-intrinsic mitochondrial stress from source-resolved cardio-hepatic signaling, highlighting hepatic ketogenesis, fibroblast growth factor 21 (FGF21), mitochondrial DNA (mtDNA)-dependent inflammatory pathways, and extracellular vesicle-mediated cargo transfer as mechanistically distinct examples with different levels of evidence. We further discuss biomarker limitations, HF-related hemodynamic liver injury, and therapeutic strategies ranging from established cardiometabolic unloading to emerging mitochondria-centered interventions. A stage-, phenotype-, and source-resolved framework may improve interpretation of mitochondrial signals and guide future mechanistic and translational studies in the MASLD–HF overlap.
- Open Access
- 20 July 2026
- Published by MDPI AG in Preprints.org
Mitochondrial Distress Signals at the Heart-Liver Interface: Molecular Links Between MASLD and Heart Failure
Mitochondrial distress signaling provides a mechanistic link between local organelle dysfunction and systemic cardio-hepatic remodeling. In metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF), hepatic nutrient overload and cardiac energy-demand mismatch generate distinct but convergent disturbances in oxidative metabolism, mitochondrial dynamics, mitophagy, and redox control. These changes alter the production, localization, and release of mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, and extracellular vesicle-associated mitochondrial cargo, enabling stressed tissues to influence distant organs. This review examines how stage-dependent bioenergetic remodeling and defective mitochondrial quality control shape distress-signal generation in MASLD and HF. We further discuss the context-dependent roles of succinate, β-hydroxybutyrate, mitochondrial DNA-dependent innate immune signaling, and extracellular vesicle-mediated cargo transport in heart–liver communication. Finally, we summarize established cardiometabolic therapies and emerging mitochondria-centered strategies that reduce substrate overload, restore organelle resilience, or limit inflammatory signal propagation. Integrating these mechanisms positions mitochondrial distress signaling as a unifying framework for understanding the bidirectional relationship between MASLD and HF and for identifying biomarkers and therapeutic targets at the heart-liver interface.
- 20 July 2026
- Published by MDPI AG in Preprints.org
Open AccessMitochondrial Distress Signals at the Heart-Liver Interface: Molecular Links Between MASLD and Heart Failure
Mitochondrial distress signaling provides a mechanistic link between local organelle dysfunction and systemic cardio-hepatic remodeling. In metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF), hepatic nutrient overload and cardiac energy-demand mismatch generate distinct but convergent disturbances in oxidative metabolism, mitochondrial dynamics, mitophagy, and redox control. These changes alter the production, localization, and release of mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, and extracellular vesicle-associated mitochondrial cargo, enabling stressed tissues to influence distant organs. This review examines how stage-dependent bioenergetic remodeling and defective mitochondrial quality control shape distress-signal generation in MASLD and HF. We further discuss the context-dependent roles of succinate, β-hydroxybutyrate, mitochondrial DNA-dependent innate immune signaling, and extracellular vesicle-mediated cargo transport in heart–liver communication. Finally, we summarize established cardiometabolic therapies and emerging mitochondria-centered strategies that reduce substrate overload, restore organelle resilience, or limit inflammatory signal propagation. Integrating these mechanisms positions mitochondrial distress signaling as a unifying framework for understanding the bidirectional relationship between MASLD and HF and for identifying biomarkers and therapeutic targets at the heart-liver interface.
- 30 September 2023
- Published by Elsevier in Cancer Letters
- Vol. 576, 216405
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
- 30 September 2023
- Published by Elsevier in Cancer Letters
- Vol. 576, 216405
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
- Open Access
- 6 September 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Efficacy of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in advanced or metastatic colorectal cancer patients with metastatic microsatellite stable (MSS) or mismatch repair profcient (pMMR) : a systematic review and meta-analysis
INPLASY202390019 Efficacy of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in advanced or metastatic colorectal cancer patients with metastatic microsatellite stable (MSS) o…
- 6 September 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessEfficacy of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in advanced or metastatic colorectal cancer patients with metastatic microsatellite stable (MSS) or mismatch repair profcient (pMMR) : a systematic review and meta-analysis
INPLASY202390019 Efficacy of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in advanced or metastatic colorectal cancer patients with metastatic microsatellite stable (MSS) o…
- Open Access
- 10 April 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Comparison of enteral immunonutrition and enteral nutrition in patients undergoing gastric cancer surgery:a systematic review and network meta-analysis of randomized controlled trials
INPLASY202340030 Comparison of enteral immunonutrition and enteral nutrition in patients undergoing gastric cancer surgery:a systematic review and network meta-analysis of randomized controlled tri…
- 10 April 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessComparison of enteral immunonutrition and enteral nutrition in patients undergoing gastric cancer surgery:a systematic review and network meta-analysis of randomized controlled trials
INPLASY202340030 Comparison of enteral immunonutrition and enteral nutrition in patients undergoing gastric cancer surgery:a systematic review and network meta-analysis of randomized controlled tri…
- Open Access
Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer
Esophageal cancer is one of the malignant tumors with poor prognosis in China. Currently, the treatment of esophageal cancer is still based on surgery, especially in early and mid-stage patients, to achieve the goal of radical cure. However, esophageal cancer is a kind of tumor with a high risk of recurrence and metastasis, and locoregional recurrence and distant metastasis are the leading causes of death after surgery. Although multimodal comprehensive treatment has advanced in recent years, the prediction, prevention and treatment of postoperative recurrence and metastasis of esophageal cancer are still unsatisfactory. How to reduce recurrence and metastasis in patients after surgery remains an urgent problem to be solved. Given the clinical demand for early detection of postoperative recurrence of esophageal cancer, clinical and basic research aiming to meet this demand has been a hot topic, and progress has been observed in recent years. Therefore, this article reviews the research progress on the factors that influence and predict postoperative recurrence of esophageal cancer, hoping to provide new research directions and treatment strategies for clinical practice.
Open AccessResearch Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer
Esophageal cancer is one of the malignant tumors with poor prognosis in China. Currently, the treatment of esophageal cancer is still based on surgery, especially in early and mid-stage patients, to achieve the goal of radical cure. However, esophageal cancer is a kind of tumor with a high risk of recurrence and metastasis, and locoregional recurrence and distant metastasis are the leading causes of death after surgery. Although multimodal comprehensive treatment has advanced in recent years, the prediction, prevention and treatment of postoperative recurrence and metastasis of esophageal cancer are still unsatisfactory. How to reduce recurrence and metastasis in patients after surgery remains an urgent problem to be solved. Given the clinical demand for early detection of postoperative recurrence of esophageal cancer, clinical and basic research aiming to meet this demand has been a hot topic, and progress has been observed in recent years. Therefore, this article reviews the research progress on the factors that influence and predict postoperative recurrence of esophageal cancer, hoping to provide new research directions and treatment strategies for clinical practice.
- Open Access
- 14 June 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-10
Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis
Background: Peritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis. Methods: This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PubMed, Embase, Cochrane, Web of Knowledge, and ClinicalTrials.gov databases were screened from inception of the review to March 11, 2022. Ten studies were included in qualitative and quantitative analysis. Results: A total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. The results showed that the OS of CRS + HIPEC group was higher than that of control group (HR: 0.53, 95% CI: 0.38–0.73; P < 0.00001, I2 = 82.9%); the heterogeneity of the studies was large. The subgroup analysis showed that the OS of CRS and HIPEC group was higher than that of PC group (HR: 0.37, 95% CI: 0.30–0.47; P = 0.215, I2 = 31%) and higher than that in CRS group (HR: 0.73, 95% CI: 0.49–1.07; P = 0.163, I2 = 44.8%); the heterogeneity of the studies was low. In the OPEN group, the OS of THE CRS and HIPEC groups was higher than that in the control group (HR: 0.51, 95% CI: 0.38–0.70; P = 0.353, I2 = 3.9%); OPEN group showed lower heterogeneity. The OS of 60–100-min group was higher than that in the control group (HR: 0.65, 95% CI: 0.49–0.88; P = 0.172, I2 = 37.4%); the heterogeneity of the studies was low. Sensitivity analysis showed that there was no significant difference in the results of the combined analysis after each study was deleted. The results of publication bias showed that the P-value of Egger and Begg tests was 0.078 > 0.05, indicating that there is no publication bias. Conclusions: CRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasis
- 14 June 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-10
Open AccessEffect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis
Background: Peritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis. Methods: This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PubMed, Embase, Cochrane, Web of Knowledge, and ClinicalTrials.gov databases were screened from inception of the review to March 11, 2022. Ten studies were included in qualitative and quantitative analysis. Results: A total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. The results showed that the OS of CRS + HIPEC group was higher than that of control group (HR: 0.53, 95% CI: 0.38–0.73; P < 0.00001, I2 = 82.9%); the heterogeneity of the studies was large. The subgroup analysis showed that the OS of CRS and HIPEC group was higher than that of PC group (HR: 0.37, 95% CI: 0.30–0.47; P = 0.215, I2 = 31%) and higher than that in CRS group (HR: 0.73, 95% CI: 0.49–1.07; P = 0.163, I2 = 44.8%); the heterogeneity of the studies was low. In the OPEN group, the OS of THE CRS and HIPEC groups was higher than that in the control group (HR: 0.51, 95% CI: 0.38–0.70; P = 0.353, I2 = 3.9%); OPEN group showed lower heterogeneity. The OS of 60–100-min group was higher than that in the control group (HR: 0.65, 95% CI: 0.49–0.88; P = 0.172, I2 = 37.4%); the heterogeneity of the studies was low. Sensitivity analysis showed that there was no significant difference in the results of the combined analysis after each study was deleted. The results of publication bias showed that the P-value of Egger and Begg tests was 0.078 > 0.05, indicating that there is no publication bias. Conclusions: CRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasis